Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Extended-release niacin/laropiprant for lipid management: observational study in clinical practice.
Steinhagen-Thiessen E, Dänschel W, Buffleben C, Smolka W, Pittrow D, Hildemann SK. Steinhagen-Thiessen E, et al. Among authors: hildemann sk. Int J Clin Pract. 2013 Jun;67(6):527-35. doi: 10.1111/ijcp.12088. Epub 2013 Feb 26. Int J Clin Pract. 2013. PMID: 23437867 Clinical Trial.
Type II diabetes and its therapy in clinical practice - results from the standardised non-interventional registry SIRTA.
Gallwitz B, Kusterer K, Hildemann S, Fresenius K. Gallwitz B, et al. Among authors: hildemann s. Int J Clin Pract. 2014 Dec;68(12):1442-53. doi: 10.1111/ijcp.12497. Epub 2014 Oct 9. Int J Clin Pract. 2014. PMID: 25298194 Free article.
[Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients].
Hildemann SK, Fischer HM, Pittrow D, Bohlscheid V. Hildemann SK, et al. Fortschr Med Orig. 2003;121(1):27-32. Fortschr Med Orig. 2003. PMID: 15117066 German.
Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany.
Gitt AK, Sonntag F, Jannowitz C, Weizel A, Karmann B, Schaefer JR, Pittrow D, Hildemann SK. Gitt AK, et al. Among authors: hildemann sk. Curr Med Res Opin. 2016;32(3):417-26. doi: 10.1185/03007995.2015.1120715. Epub 2015 Dec 29. Curr Med Res Opin. 2016. PMID: 26568400
Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
Dänschel W, Steinhagen-Thiessen E, Buffleben C, Pittrow D, Hildemann SK. Dänschel W, et al. Curr Med Res Opin. 2013 Jan;29(1):33-40. doi: 10.1185/03007995.2012.750602. Epub 2012 Nov 30. Curr Med Res Opin. 2013. PMID: 23157464 Clinical Trial.
Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice.
Hildemann SK, Barho C, Karmann B, Darius H, Bode C. Hildemann SK, et al. Curr Med Res Opin. 2008 Oct;24(10):2777-84. doi: 10.1185/03007990802381406. Epub 2008 Aug 21. Curr Med Res Opin. 2008. PMID: 18721490 Clinical Trial.
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.
Hostalek U, Gwilt M, Hildemann S. Hostalek U, et al. Among authors: hildemann s. Drugs. 2015 Jul;75(10):1071-94. doi: 10.1007/s40265-015-0416-8. Drugs. 2015. PMID: 26059289 Free PMC article. Review.
Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice.
Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K. Hildemann SK, et al. Curr Med Res Opin. 2007 Apr;23(4):713-9. doi: 10.1185/030079907x178702. Curr Med Res Opin. 2007. PMID: 17407627 Clinical Trial.
Patients received--almost all after statin pre-treatment--ezetimibe 10 mg plus simvastatin 10 mg (study 1: 15%, study 2: 16%), 20 mg (in 68% each), 40 mg (12%/10%) or 80 mg (1%/1%) as fixed dose combinations over 3 months (dosage at investigator's discretion). ...
Patients received--almost all after statin pre-treatment--ezetimibe 10 mg plus simvastatin 10 mg (study 1: 15%, study 2: 16%), 20 mg (in 68% …
Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care.
Hildemann S, Karmann B, Pittrow D, Barho C, Darius H, Bode C. Hildemann S, et al. Curr Med Res Opin. 2008 Jun;24(6):1659-68. doi: 10.1185/03007990802134755. Epub 2008 May 2. Curr Med Res Opin. 2008. PMID: 18457604
29 results
Jump to page
Feedback